Search Results

You are looking at 1 - 3 of 3 items for :

  • weight loss program x
  • Hormones and Cancer x
Clear All
Xiaoya Zheng Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Xiaoya Zheng in
Google Scholar
PubMed
Close
,
Shanshan Yu Pathology Department, Chongqing Medical University, Chongqing, China

Search for other papers by Shanshan Yu in
Google Scholar
PubMed
Close
,
Jian Long Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Jian Long in
Google Scholar
PubMed
Close
,
Qiang Wei Prevention of Disease Department, Chongqing Jiulongpo District Hospital of Traditional Chinese Medicine, Chongqing, China

Search for other papers by Qiang Wei in
Google Scholar
PubMed
Close
,
Liping Liu Department of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Liping Liu in
Google Scholar
PubMed
Close
,
Chun Liu Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Chun Liu in
Google Scholar
PubMed
Close
, and
Wei Ren Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Wei Ren in
Google Scholar
PubMed
Close

dysphagia were more frequent in patients with PTL than in patients with DSVPTC. Symptoms such as neck pain, hoarseness, weight loss and fever were present in two to four patients with PTL, while these symptoms were very rare in patients with DSVPTC. Compared

Open access
Ruth Percik Institute of Endocrinology, Diabetes and Metabolism, Sheba Medical Centre, Ramat Gan, Israel

Search for other papers by Ruth Percik in
Google Scholar
PubMed
Close
,
Sherwin Criseno Department of Endocrinology, University Hospital Birmingham, Birmingham, UK

Search for other papers by Sherwin Criseno in
Google Scholar
PubMed
Close
,
Safwaan Adam Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, UK

Search for other papers by Safwaan Adam in
Google Scholar
PubMed
Close
,
Kate Young Royal Marsden Hospital, London, UK

Search for other papers by Kate Young in
Google Scholar
PubMed
Close
, and
Daniel L Morganstein Department of Endocrinology, Chelsea and Westminster Hospital, London, UK
Royal Marsden Hospital, London, UK

Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed
Close

-L1 inhibition and usually manifests with weakness and loss of appetite without clinical or laboratory or radiological evidence of wider pituitary dysfunction ( 20 , 21 ). IAD is therefore a clinically distinct pituitary abnormality, caused by

Open access
Daniel Alexander Hescheler Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
European Institute for Molecular Imaging (EIMI), University of Münster, Münster, Germany

Search for other papers by Daniel Alexander Hescheler in
Google Scholar
PubMed
Close
,
Milan Janis Michael Hartmann Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Milan Janis Michael Hartmann in
Google Scholar
PubMed
Close
,
Burkhard Riemann Department of Nuclear Medicine, University Hospital Münster, Münster, Germany

Search for other papers by Burkhard Riemann in
Google Scholar
PubMed
Close
,
Maximilian Michel Institute of Zoology, University of Cologne Germany, Cologne, Germany

Search for other papers by Maximilian Michel in
Google Scholar
PubMed
Close
,
Christiane Josephine Bruns Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Christiane Josephine Bruns in
Google Scholar
PubMed
Close
,
Hakan Alakus Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Hakan Alakus in
Google Scholar
PubMed
Close
, and
Costanza Chiapponi Department of General, Visceral, Tumor and Transplant Surgery, University Hospital Cologne, Cologne, Germany

Search for other papers by Costanza Chiapponi in
Google Scholar
PubMed
Close

, 82%; HTN, 82%; fatigue, 59%; nausea, 59%; proteinuria, 59%) Secondary endpoints: ORR: 24% Median PFS: 7.4 months Median OS Hypertension, diarrhea, fatigue, anorexia, weight loss, nausea  Lenvatinib  NCT02726503 ATC estimated enrolment: 39

Open access